NEW YORK, Oct. 19 - Invitrogen has been granted a non-exclusive sub-license from Gryphon Sciences to use its Native Chemical Ligation patent, which allow researchers to synthesize proteins using chemical, rather than biological means, Gryphon said on Friday.
The patent, numbered 6,184,344 and entitled "Synthesis of Proteins by Native Chemical Ligation," covers processes for making proteins that retain the biologic activity of the native molecule and can have specific functionality built into them, according to Gryphon.
Financials terms of the deal were not disclosed.
"By developing new products using Gryphon's NCL technology, we will extend our offerings in proteomics as well as broaden our molecular biology operating system," Lyle Turner, chairman and CEO of Invitrogen, said in a statement released by South San Francisco, Calif.-based Gryphon.
Invitrogen was awarded non-exclusive rights to the NCL patent one day after the company filed suit against Incyte Genomics for alleged patent infringement.
As GenomeWeb reported on Thursday, the primary patent in contention is Invitrogen’s SuperScript form of RNase H minus reverse transcriptase, which Invitrogen said was sold to Incyte under a research-use-only license.
“We have been trying for several years to secure a license from Incyte for commercial use,” Paul Goodson, vice president of investor relations at Carlsbad, Calif.-based Invitrogen, said. “We believe this is the only way we will be able to enforce the patent. Incyte is creating gene clones and bioinformatic information which they have gotten directly from the use of this product and are selling it, which violates research-usage license.”
Incyte would not comment on the suit.